Costs of occupational asthma and of occupational chronic obstructive pulmonary disease

Current Opinion in Allergy and Clinical Immunology

Volumn 3, Issue 2, 2003, Pages 109-114

  Moscato, Gianna ^a,b   Rampulla, Ciro ^a  

^a Scientific Institute of Pavia   (Italy)

^b IRCCS   (Italy)

Author keywords

Costs; Economics; Occupational asthma; Occupational COPD; Socioeconomic factors

Indexed keywords

CHRONIC OBSTRUCTIVE LUNG DISEASE; COST OF ILLNESS; EMPLOYABILITY; EMPLOYMENT; HEALTH CARE COST; HUMAN; MONEY; OCCUPATIONAL ASTHMA; OCCUPATIONAL DISEASE; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; OUTCOMES RESEARCH; PRIMARY PREVENTION; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SECONDARY PREVENTION; SOCIOECONOMICS; WORKMAN COMPENSATION; WORKPLACE;

ASTHMA; COSTS AND COST ANALYSIS; HUMANS; OCCUPATIONAL DISEASES; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; UNITED STATES;

EID: 0038077375     PISSN: 15284050     EISSN: None     Source Type: Journal    
DOI: 10.1097/00130832-200304000-00004     Document Type: Review

References (58)

1. Collins JG. Prevalence of selected chronic conditions: United States, 1990-1992. Vital Health Stat 1997; 10:1-89.
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349:1498-1504.
3. Mannino DM, Homa DM, Pertowski CA, et al. Surveillance for asthma: United States, 1960-1995. MMWR Morb Mortal Wkly Rep 1998; 47:1-28.
4. National Heart Lung and Blood Institute. Morbidity and Mortality: chart book on cardiovascular, lung and blood diseases. Hyattsville, MD: US Department of Health and Human Services National Heart Lung and Blood Institute; 1998.
5. Mannino DM. How much asthma is occupationally related? Occ Med 2000; 15:359-368.
6. Blanc PD, Toren K. How much adult asthma can be attributed to occupational factors? Am J Med 2000; 107:580-587.
7. Malo JL. How much adult asthma can be attributed to occupational factors (revisited)? Chest 2002; 118:1232-1234.
8. Viegi G, Di Pede C. Chronic obstructive lung diseases and occupational exposure. Curr Opin Allergy Clin Immunol 2002; 2:115-121. This is a thorough review highlighting the substantial contribution of occupational factors to the development of COPD and asthma.
9. Rosenberg N, Garnier R, Rousselin X, et al. Clinical and socio-professional fate of isocyanate-induced asthma. Clin Allergy 1987; 17:55-61.
10. Venables KM, Davison AG, Newman Taylor AJ. Consequences of occupational asthma. Respir Med 1989; 83:437-440.
11. Gannon PFG, Weir DC, Robertson AS, et al. Health, employment, and financial outcomes in workers with occupational asthma. Br J Ind Med 1993; 50:491-496.
12. Marabini A, Dimich-Ward H, Kwan SYL, et al. Clinical and socio-economic features of subjects with red cedar asthma. Chest 1993; 104:821-824.
13. Ameille J, Pairon JC, Bayeux MC, et al. Consequences of occupational asthma on employment and financial status: a follow-up study. Eur Respir J 1997; 10:55-58.
14. Moscato G, Dellabianca A, Perfetti L, et al. Occupational asthma: a longitudinal study on the clinical and socioeconomic outcome after diagnosis. Chest 1999; 115:249-256.
15. Gassert TH, Hu H, Kelsey KT, et al. Long-term health and employment outcomes of occupational asthma and their determinants. J Occup Environ Med 1998; 40:481-491.
16. Ross DJ, McDonald JC. Health and employment after diagnosis of occupational asthma: a descriptive study. Occup Med (Lond) 1998; 48:219-225.
17. Anderson EBE, Toren K. Consequences of reported occupational asthma. (Abstract) Eur Respir J 2001; 18 (Suppl 33):509s.
18. Gautrin D, Lemiere C. Persistence of airway responsiveness to occupational agents: what does it matter? Curr Opin Allergy Clin Immunol 2002; 2:123-127.
19. Malo JL, Dewitte JD, Cartier A, et al. The Quebec system of indemnification for occupational asthma: description, efficacy, and costs. Rev Mal Respir 1993; 10:313-323.
20. Leigh JP, Cone JE, Harrison R. Costs of occupational injuries and illnesses in California. Prev Med 2001; 32:393-406.
21. Leigh JP, Romano PS, Schenker MB, et al. Costs of occupational COPD and asthma. Chest 2002; 121:264-272. This study is mainly of interest because it was the first one specifically devoted to the evaluation of direct and indirect costs of occupational COPD and asthma. The main merit of the study is that it utilized national data and a standard method which allowed a comparison with other cost of illness estimates.
22. Bernstein IL, Bernstein DI, Chan-Yeung M, Malo J-L. Definition and classification of asthma. In: Bernstein IL, Chan-Yeung M, Malo J-L, Bernstein DI, editors. Asthma in the workplace. New York: Marcel Dekker Inc.; 1999. pp. 1-3.
23. Malo J-L, Chan-Yeung M. Occupational asthma. J Allergy Clin Immunol 2001; 108:3317-3328.
24. Malo GL, Ghezzo H, l'Archeveque J, et al. Is the clinical history a satisfactory means of diagnosing occupational asthma? Am Rev Respir Dis 1991; 143:528-532.
25. Ortega H, Kreiss K, Schill DP, et al. Fatal asthma powdering shark cartilage and review of fatal occupational asthma literature. Am J Ind Med 2002; 42:50-54.
26. Tarlo SM, Leung K, Broder I, et al. Asthmatic subjects symptomatically worse at work: prevalence and characterization among a general asthma clinic population. Chest 2000; 18:1309-1314.
27. Larbanois A, Jamart J, Delwiche JP, et al. Socioeconomic outcome of subjects experiencing asthma symptoms at work. Eur Respir J 2002; 19:1107-1113. This very interesting paper was the first to demonstrate that work-related asthma without demonstrable occupational asthma is associated with considerable socioeconomic consequences.
28. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163:1256-1276.
29. Viegi G, Scognamiglio A, Baldacci S, et al. Epidemiology of chronic obstructive pulmonary disease (COPD). Respiration 2001; 68:4-19.
30. Becklake MR. Occupational exposures: evidence for a causal association with chronic obstructive pulmonary disease. Am Rev Respir Dis 1989; 140 (3 Pt 2):S85-S91.
31. Donato F, Pasini GF, Buizza MA, et al. Tobacco smoking, occupational exposure and chronic respiratory disease in an Italian industrial area. Monaldi Arch Chest Dis 2000; 55:194-200.
32. Meredith SK, Taylor VM, McDonald JC. Occupational respiratory disease in the United Kingdom 1989: a report to the British Thoracic Society and the Society of Occupational Medicine by the SWORD project group. Br J Ind Med 1991; 48:292-298.
33. Balmes J, Becklake M, Blanc P, et al. ATS statement on occupational contribution to the burden of airway disease. Am J Respir Crit Care Med (in press).
34. Karjalainen A, Kurppa K, Martikainen R, et al. Work is related to a substantial portion of adult-onset asthma incidence in the Finnish population. Am J Respir Crit Care Med 2001; 15:565-568.
35. Arif AA, Whitehead LW, Delclos GL, et al. Prevalence and risk factors of work related asthma by industry among United States workers: data from the third national health and nutrition examination survey. Occup Environ Med 2002; 59:505-511. This study performed on a large sample of general population calculated the PAR for occupational asthma and indicated the main industries at risk of occupational asthma that could be targeted for future intervention.
36. Petsonk EL. Work-related asthma and implications for the general public. Environ Health Perspect 2002; 110 (Suppl 4):569-572.
37. Hnizdo E, Sullivan PA, Bang KM, et al. Association between chronic obstructive pulmonary disease and employment by industry and occupation in the US population: a study of data from the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2002; 156:738-746. This study evaluated the PAR for occupational COPD in a large sample of the general population and identified industries in which the odds ratio for COPD is increased. The data are especially useful for specific preventive intervention.
38. Bernstein DI. Management of natural rubber latex allergy. J Allergy Clin Immunol 2002; 110 (2 Suppl):S111-116. This excellent review suggested a stepwise approach for managing NRL allergy, highlighting the physician's responsibilities in diagnosis, definition of impairment and disability, and in advising employers regarding effective interventions.
39. Vandenplas O, Jamart J, Delwiche J-P, et al. Occupational asthma caused by natural rubber latex: outcome according to cessation or reduction of exposure. J Allergy Clin Immunol 2002; 109:125-130. This authors of this paper suggest that reduction of exposure to latex is associated with fewer socioeconomic consequences than removal from exposure.
40. Cannon J, Cullinan P, Newman Taylor A. Consequence of occupational asthma. BMJ 1995; 311:602-603.
41. Tarlo SM, Boulet LP, Cartier A, et al. Canadian Thoracic Society Guidelines for occupational asthma. Can Respir J 1998; 5:289-300.
42. Bernstein IL, Keskinen H, Malo JL. Medicolegal and compensation aspects. In: Bernstein IL, Chan-Yeung M, Malo J-L, Bernstein DI, editors. Asthma in the workplace. New York: Marcel Dekker Inc.; 1999. pp. 279-297.
43. Tarlo SM, Liss GM, Yeung KS. Changes in rates and severity of compensation claims for asthma due to diisocyanates: a possible effect of medical surveillance measures. Occup Environ Med 2002; 59:58-62. This article is of importance as it reports data on the effectiveness of a medical surveillance program. It indicates a beneficial outcome for workers exposed to isocyanates.
44. Tarlo SM, Liss GM. Diisocyanate-induced asthma: diagnosis, prognosis, and effects of medical surveillance measures. Appl Occup Environ Hyg 2002; 17:902-908. This review on diisocyanate asthma highlights the benefit on the outcome of the disease from medical surveillance measures.
45. Liss GM, Tarlo SM. Natural rubber latex-related occupational asthma: association with interventions and glove changes over time. Am J Ind Med 2001; 40:347-353. This was one of the first studies reporting data on the benefit from medical surveillance systems. It showed that workplace interventions which reduce exposure to latex are associated temporally with declines in the number of cases of latex occupational asthma.
46. Tarlo SM, Easty A, Eubanks K, et al. Outcomes of a natural rubber latex control program in an Ontario teaching hospital. J Allergy Clin Immunol 2001; 108:628-633. The relevance of this study firstly derives from the large population examined to evaluate the effects of intervention to reduce NRL allergy. It also firstly calculates some parameters (number of visits to the allergy department) contributing to the direct costs of NRL allergy.
47. Sussman GL, Beezhold DH, Liss G. Latex allergy: historical perspective. Methods 2002; 27:3-9. This review highlights that institution of policies to use low-protein, powder-free gloves results in reduction of visits for NRL allergy and of compensation claims due to occupational asthma.
48. Phillips VL, Goodrich MA, Sullivan TJ. Health care worker disability due to latex allergy and asthma: cost analysis. Am J Public Health 1999; 89:1024-1028.
49. Rice DP. Estimating the cost of illness. Health Economics Series No.6, Public Health Service, Washington, DC: US Government Printing Office; 1966.
50. Korn RJ, Dockery DW, Speizer FE, et al. Occupational exposures and chronic respiratory symptoms: a population-based study. Am Rev Respir Dis 1987; 136:298-304.
51. Leigh JP, Markowitz SB, Fahs MC, et al. Occupational injury and illnesses in the U.S.: estimates of costs, mortality and morbidity. Arch Intern Med 1997; 157:1557-1568.
52. Rodgers CB. Estimating jury compensation for pain and suffering in product liability cases involving non fatal personal injury. J Forensic Econ 1993; 6:251-262.
53. Malo JL, Boulet LP, Dewitte JD, et al. Quality of life of subjects with occupational asthma. J Allergy Clin Immunol 1993; 91:1121-1127.
54. Weiss KB, Sullivan SD. The economic costs of asthma: a review and conceptual model. Pharmacoeconomics 1993; 4:14-30.
55. Smith DH, Malone DC, Lawson KA, et al. A national estimate of the economic costs of asthma. Am J Respir Crit Care Med 1997; 156 (3 Pt 1):787-793.
56. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000; 117 (2 Suppl):5S-9S.
57. Wilson L, Devine EB, So K. Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema. Respir Med 2000; 94:204-213.
58. Ward MM, Javitz HS, Smith WM, et al. Direct medical cost of chronic obstructive pulmonary disease in the U.S.A. Respir Med 2000; 94:1123-1129.